Limit on lab-grown human embryos dropped by stem-cell body
By Nidhi Subbaraman,
Nature
| 05. 26. 2021
The International Society for Stem Cell Research relaxed the famous 14-day rule on culturing human embryos in its latest research guidelines.
The international body representing stem-cell scientists has torn up a decades-old limit on the length of time that scientists should grow human embryos in the lab, giving more leeway to researchers who are studying human development and disease.
Previously, the International Society for Stem Cell Research (ISSCR) recommended that scientists culture human embryos for no more than two weeks after fertilization. But on 26 May, the society said it was relaxing this famous limit, known as the ‘14-day rule’. Rather than replace or extend the limit, the ISSCR now suggests that studies proposing to grow human embryos beyond the two-week mark be considered on a case-by-case basis, and be subjected to several phases of review to determine at what point the experiments must be stopped.
The ISSCR made this change and others to its guidelines for biomedical research in response to rapid advances in the field, including the ability to create embryo-like structures from human stem cells. In addition to relaxing the ‘14-day rule’, for instance, the group advises against editing genes in human embryos until the safety of genome...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...
By Staff, The Medicine Maker | 03.21.2025
"The Promise and Peril of CRISPR" cover by Johns Hopkins University Press
As a paediatrician taking care of children with sickle cell disease, Neal Baer, a Harvard Medical School graduate, was in awe of the power of CRISPR technologies. Later...